RxDoctor Payments Data

Christopher Luthi, MD

Internal Medicine · Milford, CTNPI 1518100072

Payments from drug & device makers

$295in general payments, 2019–2025

Across 19 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$90
  • Boehringer Ingelheim$77
  • AstraZeneca$49
  • Merck$32
  • Novo Nordisk$16
  • Takeda Pharmaceuticals U.S.A., Inc.$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$295 in reported general payments places this provider in the 60th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$24,962
Medicare patients
77
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban237$70,863
OtezlaApremilast25$39,297
JanuviaSitagliptin Phosphate134$36,479
EntrestoSacubitril/Valsartan50$17,583
JardianceEmpagliflozin56$17,037
XareltoRivaroxaban51$14,718
TivicayDolutegravir Sodium11$13,661
MyrbetriqMirabegron54$12,694
Enoxaparin Sodium42$9,219
TradjentaLinagliptin33$8,891
Sucralfate25$7,656
Spiriva RespimatTiotropium Bromide13$7,593
FarxigaDapagliflozin Propanediol23$7,012
Sevelamer Carbonate25$6,253
Aripiprazole40$4,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$70,863237 claims
MerckJanuvia$32$36,479134 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$77$33,521102 claims
AstraZenecaFarxiga$49$7,01223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →